Tell your friends about this item:
Biosimilarity: The FDA Perspective Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA) 1st edition
Price
$ 272.99
excl. VAT
Ordered from remote warehouse
Expected to be ready for shipping Jul 8 - 20
Our customers say:
Add to your iMusic wish list
Biosimilarity: The FDA Perspective
Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA)
The focus of this book is on how the US FDA will approve biosimilar drugs. The European scene is well developed with specific guidelines that are already in place. However, these guidelines do not apply to the thinking of the FDA in approving these products.
456 pages, 79 colour illustrations, 43 black & white tables
| Media | Books Hardcover Book (Book with hard spine and cover) |
| Released | July 25, 2018 |
| ISBN13 | 9781498750394 |
| Publishers | Taylor & Francis Inc |
| Pages | 398 |
| Dimensions | 261 × 187 × 29 mm · 1.10 kg |
| Language | English |
